ArticleBioinformation2026
Transfusion requirements in acute coronary syndrome patients undergoing thrombolysis or anticoagulation: A retrospective cohort study.
Article in Bioinformation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bleeding complications and associated transfusion requirements remain a significant concern in patients with Acute Coronary Syndrome (ACS) undergoing anticoagulation or thrombolysis, yet data on transfusion needs and risk factors in resource-limited settings are limited. Therefore, it is of interest to assess transfusion requirements in 85 patients with Acute Coronary Syndrome (ACS) undergoing anticoagulation or thrombolysis at UPUMS, Saifai, from December 2024 to April 2025. Major bleeding requiring transfusion occurred in 4.7% (n=4) of patients, predominantly due to gastrointestinal sources (50%). The mean transfusion requirement was 2 units of packed red blood cells per bleeding event. Independent risk factors for major bleeding were age >65 years, chronic kidney disease and triple therapy (antiplatelet + anticoagulant + fibrinolytic). Bleeding was associated with significantly higher 30-day mortality (25% versus 5% in non-bleeders), highlighting the need for individualized antithrombotic strategies in ACS management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.